AstraZeneca PLC (AZNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZNN) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$5.13 Billion ≈ $295.46 Million USD) by net assets (MX$45.97 Billion ≈ $2.65 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also explore AZNN current and non-current assets for the complete picture of this company's asset base.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. For the full company profile with market capitalisation and key ratios, see market cap of AstraZeneca PLC.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.050x |
|
GE Aerospace
NYSE:GE
|
0.118x |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
-0.001x |
|
General Electric Company
SA:GEOO34
|
0.457x |
|
Novartis AG
MX:NVSN
|
0.049x |
|
Lam Research Corp
NASDAQ:LRCX
|
0.146x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.060x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2024)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2024. See AstraZeneca PLC (AZNN) net assets for net asset value and shareholders' equity analysis.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | MX$40.87 Billion ≈ $2.35 Billion |
MX$11.86 Billion ≈ $682.60 Million |
0.290x | +9.68% |
| 2023-12-31 | MX$39.17 Billion ≈ $2.25 Billion |
MX$10.36 Billion ≈ $596.39 Million |
0.265x | -0.03% |
| 2022-12-31 | MX$37.06 Billion ≈ $2.13 Billion |
MX$9.81 Billion ≈ $564.45 Million |
0.265x | +74.37% |
| 2021-12-31 | MX$39.29 Billion ≈ $2.26 Billion |
MX$5.96 Billion ≈ $343.17 Million |
0.152x | -50.54% |
| 2020-12-31 | MX$15.64 Billion ≈ $899.97 Million |
MX$4.80 Billion ≈ $276.18 Million |
0.307x | +50.87% |
| 2019-12-31 | MX$14.60 Billion ≈ $840.00 Million |
MX$2.97 Billion ≈ $170.87 Million |
0.203x | +9.12% |
| 2018-12-31 | MX$14.04 Billion ≈ $808.24 Million |
MX$2.62 Billion ≈ $150.67 Million |
0.186x | -13.30% |
| 2017-12-31 | MX$16.64 Billion ≈ $957.75 Million |
MX$3.58 Billion ≈ $205.91 Million |
0.215x | -13.54% |
| 2016-12-31 | MX$16.67 Billion ≈ $959.31 Million |
MX$4.14 Billion ≈ $238.55 Million |
0.249x | +38.46% |
| 2015-12-31 | MX$18.51 Billion ≈ $1.07 Billion |
MX$3.32 Billion ≈ $191.30 Million |
0.180x | -50.01% |
| 2014-12-31 | MX$19.65 Billion ≈ $1.13 Billion |
MX$7.06 Billion ≈ $406.19 Million |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more